Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
作者信息
Kucharz Eugeniusz Józef, Kotulska-Kucharz Anna
机构信息
Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical University of Silesia, Katowice, Poland.
出版信息
Reumatologia. 2021;59(2):65-67. doi: 10.5114/reum.2021.105438. Epub 2021 Apr 27.
Abstract
摘要
相似文献
1
Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?肿瘤坏死因子α抑制剂与脱髓鞘疾病：其背后的原因是什么？
Reumatologia. 2021;59(2):65-67. doi: 10.5114/reum.2021.105438. Epub 2021 Apr 27.
2
A case report about adalimumab-induced radiologically isolated syndrome: A significant side effect of tumour necrosis factor inhibitors.一例关于阿达木单抗诱导的放射学孤立综合征的病例报告：肿瘤坏死因子抑制剂的一种显著副作用。
SAGE Open Med Case Rep. 2021 Mar 17;9:2050313X211003057. doi: 10.1177/2050313X211003057. eCollection 2021.
3
Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.肿瘤坏死因子-α阻滞剂治疗期间发生的脱髓鞘性神经病的长期病程。
Arch Neurol. 2009 Apr;66(4):490-7. doi: 10.1001/archneurol.2009.11.
4
Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk.比较 TNF-α 抑制剂使用的终生风险与常见风险基准。
J Dermatolog Treat. 2013 Apr;24(2):101-6. doi: 10.3109/09546634.2011.595574. Epub 2011 Jul 14.
5
Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review.肿瘤坏死因子抑制剂治疗银屑病继发的脱髓鞘疾病：综述
J Dermatolog Treat. 2016 Oct;27(5):406-13. doi: 10.3109/09546634.2015.1136385. Epub 2016 Feb 2.
6
Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha.在显示肿瘤坏死因子α中枢神经系统特异性表达的转基因小鼠中的自发性炎性脱髓鞘疾病。
Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11294-8. doi: 10.1073/pnas.92.24.11294.
7
Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system.在中枢神经系统中产生肿瘤坏死因子-α的转基因小鼠中，实验性自身免疫性脑脊髓炎的严重程度增加、慢性巨噬细胞/小胶质细胞反应性增强以及脱髓鞘现象出现。
Eur J Immunol. 1997 Apr;27(4):905-13. doi: 10.1002/eji.1830270416.
8
Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.抗肿瘤坏死因子治疗后的炎性脱髓鞘事件
Cytokine. 2009 Feb;45(2):55-7. doi: 10.1016/j.cyto.2008.11.002. Epub 2008 Dec 23.
9
Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?与肿瘤坏死因子α拮抗剂相关的脱髓鞘和神经系统事件：肿瘤坏死因子α拮抗剂通过何种机制可改善类风湿性关节炎却加重多发性硬化症？
Arthritis Rheum. 2001 Sep;44(9):1977-83. doi: 10.1002/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6.
10
Risk of Demyelinating Diseases in the Central Nervous System in Patients With Inflammatory Bowel Disease Treated With Tumor Necrosis Factor Inhibitors.接受肿瘤坏死因子抑制剂治疗的炎症性肠病患者发生中枢神经系统脱髓鞘疾病的风险。
JAMA Intern Med. 2015 Dec;175(12):1990-2. doi: 10.1001/jamainternmed.2015.5396.
引用本文的文献
1
Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database.英夫利昔单抗和阿达木单抗在儿童炎症性肠病中的安全性：来自FAERS数据库的不成比例性分析。
BMC Gastroenterol. 2025 Aug 7;25(1):560. doi: 10.1186/s12876-025-04154-w.
2
Consensus Recommendations for the Management of Neurosarcoidosis: A Delphi Survey of Experts Across the United States.结节病性神经病变管理的共识性建议：一项针对美国各地专家的德尔菲调查
Neurol Clin Pract. 2025 Apr;15(2):e200429. doi: 10.1212/CPJ.0000000000200429. Epub 2025 Jan 15.
3
Case report: Breaking CNS immuno-privilege: TNFα-inhibitor triggers aseptic meningitis in a patient with rheumatoid arthritis.病例报告：打破中枢神经系统免疫豁免：TNFα 抑制剂在类风湿关节炎患者中引发无菌性脑膜炎。
Front Immunol. 2024 Sep 10;15:1432360. doi: 10.3389/fimmu.2024.1432360. eCollection 2024.
4
Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures.肿瘤坏死因子-α（TNF-α）拮抗剂在慢性炎症性风湿病中的应用：风险及其最小化措施。
Curr Drug Saf. 2024;19(4):431-443. doi: 10.2174/0115748863274863231222023853.
5
Diabetic complications and prospective immunotherapy.糖尿病并发症与前瞻性免疫疗法。
Front Immunol. 2023 Jul 7;14:1219598. doi: 10.3389/fimmu.2023.1219598. eCollection 2023.
6
Acute transverse myelitis revealing ankylosing spondylitis: A case report and literature review.急性横贯性脊髓炎揭示强直性脊柱炎：一例报告及文献综述
Clin Case Rep. 2021 Oct 4;9(10):e04878. doi: 10.1002/ccr3.4878. eCollection 2021 Oct.
本文引用的文献
1
Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.与抗 TNF 治疗相关的中枢神经系统脱髓鞘神经系统不良事件的临床病程。
J Neurol. 2021 Aug;268(8):2895-2899. doi: 10.1007/s00415-021-10460-6. Epub 2021 Feb 20.
2
Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.丹麦和瑞典基于人群的合作队列研究：肿瘤坏死因子-α抑制剂治疗关节炎患者的神经炎症事件风险。
Ann Rheum Dis. 2020 May;79(5):566-572. doi: 10.1136/annrheumdis-2019-216693. Epub 2020 Mar 11.
3
Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases.肿瘤坏死因子抑制剂与风湿性疾病患者周围神经病的风险。
Semin Arthritis Rheum. 2019 Jun;48(6):1083-1086. doi: 10.1016/j.semarthrit.2018.09.006. Epub 2018 Sep 27.
4
Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications.类风湿关节炎患者接受抗肿瘤坏死因子治疗相关脱髓鞘并发症时肿瘤坏死因子α受体超家族1A多发性硬化相关变体的频率
Ann Rheum Dis. 2018 Dec;77(12):1835-1836. doi: 10.1136/annrheumdis-2018-213183. Epub 2018 Jul 20.
5
Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review.肿瘤坏死因子抑制剂治疗银屑病继发的脱髓鞘疾病：综述
J Dermatolog Treat. 2016 Oct;27(5):406-13. doi: 10.3109/09546634.2015.1136385. Epub 2016 Feb 2.
6
Demyelination and other neurological adverse events after anti-TNF therapy.抗 TNF 治疗后的脱髓鞘和其他神经不良反应。
Autoimmun Rev. 2014 Jan;13(1):54-8. doi: 10.1016/j.autrev.2013.09.002. Epub 2013 Sep 12.
7
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.抗 TNF-α 治疗期间脱髓鞘模式：一项法国全国性调查。
Rheumatology (Oxford). 2013 May;52(5):868-74. doi: 10.1093/rheumatology/kes375. Epub 2013 Jan 3.
8
Monoclonal antibody therapy-associated neurological disorders.单克隆抗体治疗相关的神经系统疾病。
Nat Rev Neurol. 2011 Mar;7(3):165-72. doi: 10.1038/nrneurol.2011.1. Epub 2011 Jan 25.
9
Demyelinating events in rheumatoid arthritis after drug exposures.类风湿关节炎药物暴露后的脱髓鞘事件。
Ann Rheum Dis. 2010 Sep;69(9):1691-3. doi: 10.1136/ard.2009.111500. Epub 2009 Jul 23.
10
Treatment with infliximab may contribute to the development of peripheral neuropathy among the patients with rheumatoid arthritis.
Clin Rheumatol. 2007 Sep;26(9):1595-6. doi: 10.1007/s10067-007-0657-3. Epub 2007 Jun 5.
Zotero 插件